IMUX Immunic Inc.

12.19
-0.67  -5%
Previous Close 12.86
Open 13.28
Price To Book 3.09
Market Cap 155,950,815
Shares 12,793,340
Volume 234,381
Short Ratio
Av. Daily Volume 240,284
Stock charts supplied by TradingView

NewsSee all news

  1. Immunic, Inc. to Participate in Investor and Industry Conferences in June

    NEW YORK, May 29, 2020 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune

  2. Immunic, Inc. to Host Virtual R&D Day Today, May 19, 2020

    NEW YORK, May 19, 2020 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and

  3. Immunic, Inc. Receives First Regulatory Approval from German Health Authority BfArM to Initiate a Phase 2 Clinical Trial of its Selective Oral DHODH Inhibitor, IMU-838, in COVID-19 Patients

    NEW YORK, May 13, 2020 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune

  4. Immunic, Inc. Reports First Quarter 2020 Financial Results and Highlights Recent Activity

    NEW YORK, May 8, 2020 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune

  5. Immunic, Inc. Announces Pricing of $15 Million Financing

    NEW YORK, April 23, 2020 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 data due 4Q 2021.
IMU-838
Ulcerative colitis
Phase 2 data due 3Q 2020.
IMU-838
Relapsing-remitting multiple sclerosis
Phase 2 trial to commence in 2020.
IMU-838
Crohn’s disease
Phase 1 commencement of dosing announced September 18, 2019.
IMU-935
Healthy volunteers
Phase 2 data due early 2021.
IMU-838
Primary Sclerosing Cholangitis
Phase 1 trial to be initiated 1H 2020.
IMU-856
Crohn's disease
Phase 2 dosing to commence June 2020 with data due later in 2020.
IMU-838 CALVID-1
COVID-19

Latest News

  1. Immunic, Inc. to Participate in Investor and Industry Conferences in June

    NEW YORK, May 29, 2020 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune

  2. Immunic, Inc. to Host Virtual R&D Day Today, May 19, 2020

    NEW YORK, May 19, 2020 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and

  3. Immunic, Inc. Receives First Regulatory Approval from German Health Authority BfArM to Initiate a Phase 2 Clinical Trial of its Selective Oral DHODH Inhibitor, IMU-838, in COVID-19 Patients

    NEW YORK, May 13, 2020 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune

  4. Immunic, Inc. Reports First Quarter 2020 Financial Results and Highlights Recent Activity

    NEW YORK, May 8, 2020 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune

  5. Immunic, Inc. Announces Pricing of $15 Million Financing

    NEW YORK, April 23, 2020 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and

  6. Immunic, Inc. Reports that IMU-838, a Selective Oral DHODH Inhibitor, Has Demonstrated Preclinical Activity Against SARS-CoV-2 and Explores Plans for a Phase 2 Clinical Trial in COVID-19 Patients

    NEW YORK, April 21, 2020 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and

  7. Immunic, Inc. Announces Changes to Executive Team

    NEW YORK, April 17, 2020 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and

  8. Immunic, Inc. Reports Year End 2019 Financial Results and Highlights Recent Achievements

    NEW YORK, March 16, 2020 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and

  9. Immunic, Inc. to Participate in Scientific and Investor Conferences in February

    NEW YORK, Feb. 11, 2020 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and

  10. Immunic Exercises its Option for the Exclusive Worldwide License to IMU-856 from Daiichi Sankyo Co., Ltd.

    NEW YORK, Jan. 8, 2020 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune

  11. Immunic, Inc. to Present Data on IMU-856, for the First Time, at the Crohn's and Colitis Foundation's IBD Innovate Conference

    NEW YORK, Dec. 4, 2019 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune

  12. Immunic, Inc. to Participate in Investor and Scientific Conferences in December

    NEW YORK, Nov. 25, 2019 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune

  13. Immunic, Inc. Expands Board of Directors with Appointment of Biotechnology Executive Barclay A. Phillips

    NEW YORK, Nov. 19, 2019 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune

  14. Immunic, Inc. Reports Third Quarter 2019 Financial Results and Highlights Recent Activity

    NEW YORK, Nov. 7, 2019 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune

  15. Immunic, Inc. to Participate in Industry and Investor Conferences in November

    SAN DIEGO, Nov. 5, 2019 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune

  16. Immunic, Inc. Expands Board of Directors with Appointment of Industry Veteran Tamar Howson

    SAN DIEGO, Oct. 15, 2019 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and

  17. Immunic, Inc. Announces Completion of Enrollment for its Phase 2 EMPhASIS Trial of IMU-838 in Patients with Relapsing-Remitting Multiple Sclerosis

    SAN DIEGO, Oct. 10, 2019 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and

  18. Immunic, Inc. to Participate in Investor and Scientific Conferences in October

    SAN DIEGO, Sept. 30, 2019 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a clinical-stage biopharmaceutical company focused on developing potentially best-in-class, oral therapies for the treatment of chronic inflammatory

  19. Immunic, Inc. Doses First Healthy Volunteer in its Phase 1 Clinical Program of IMU-935, a Potentially Best-in-Class RORgt Inverse Agonist

    SAN DIEGO, Sept. 18, 2019 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a clinical-stage biopharmaceutical company focused on developing potentially best-in-class, oral therapies for the treatment of chronic inflammatory

  20. Immunic, Inc. to Present Selected Available and Previously Unpublished Data Regarding Lead Program, IMU-838, at the Congress of the European Committee for Treatment and Research in Multiple Sclerosis 2019

    SAN DIEGO, Sept. 11, 2019 /PRNewswire/ -- Immunic, Inc. (NASDAQ:IMUX), a clinical-stage biopharmaceutical company focused on developing potentially best-in-class, oral therapies for the treatment of chronic inflammatory